目的:探讨含米托蒽醌脂质体方案治疗高危儿童急性髓系白血病(AML)的安全性与有效性.方法:收集武汉儿童医院2022年1月至2023年2月应用含米托蒽醌脂质体方案治疗的AML高危患儿为观察组,对照组为应用去甲氧柔红霉素方案的AML高危患儿,分析患儿的临床资料,比较两组患儿治疗后骨髓恢复时间、骨髓完全缓解(CR)率,微小残留病灶(MRD)清除率及治疗相关不良反应等临床特性.结果:患儿接受含米托蒽醌脂质体化疗方案在白细胞(17 vs21 d)、粒细胞(18 vs 24 d)、血小板(17 vs 24 d)及血红蛋白(20vs26 d)计数恢复时间上均明显优于去甲氧柔红霉素组(P＜0.05).观察组治疗有效率和MRD转阴率分别为90.9％和72.7％,对照组为94.1％和76.4％,均无显著性统计学差异(P＞0.05),两组治疗总有效率类似.结论:含米托蒽醌脂质体化疗方案治疗高危儿童AML疗效不劣于去甲氧柔红霉素方案,但骨髓抑制时间明显缩短,安全性好.
Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid Leukemia
Objective:To investigate the safety and efficacy of mitoxantrone liposome in the treatment of children with high-risk acute myeloid leukemia(AML).Methods:The children with high-risk AML who received the mitoxantrone liposome regimen at Wuhan Children's Hospital from January 2022 to February 2023 were collected as the observation group,and the children with high-risk AML who received idarubicin regimen were enrolled as controls,and their clinical data were analyzed.Time to bone marrow recovery,the complete remission rate of bone marrow cytology,the clearance rate of minimal residual disease,and treatment-related adverse reactions were compared between the two groups.Results:The patients treated with mitoxantrone liposome showed shorter time to recovery of leukocytes(17 vs 21 day),granulocytes(18 vs 24 day),platelets(17 vs 24 day),and hemoglobin(20 vs 26 day)compared with those treated with idarubicin,there were statistical differences(P＜0.05).The effective rate and MRD turning negative rate in the observation group were 90.9％and 72.7％,respectively,while those in the control group were 94.1％and 76.4％,with no statistical difference(P＞0.05).The overall response rate of the two groups of patients was similar.Conclusion:The efficacy of mitoxantrone liposome is not inferior to that of idarubicin in children with high-risk AML,but mitoxantrone liposome allows a significantly shorter duration of bone marrow suppression and the safety is better.
万方数据
维普
